当前位置: 首页 >> 检索结果
481. Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study.
作者: Dean J Kereiakes.;Robert L Feldman.;A J J Ijsselmuiden.;Shigeru Saito.;Giovanni Amoroso.;James P Zidar.;S Chiu Wong.;Pieter Stella.;Steven Yakubov.;John Lasala.;David J Cohen.;Gheorghe Doros.;Donald E Cutlip.;Sunil V Rao.
来源: Circ Cardiovasc Interv. 2021年14卷9期e010609页
[Figure: see text].
482. Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease.
作者: Christopher A Rajkumar.;Matthew Shun-Shin.;Henry Seligman.;Yousif Ahmad.;Takayuki Warisawa.;Christopher M Cook.;James P Howard.;Sashiananthan Ganesananthan.;Laura Amarin.;Caitlin Khan.;Ayesha Ahmed.;Alexandra Nowbar.;Michael Foley.;Ravi Assomull.;Niall G Keenan.;Joban Sehmi.;Thomas R Keeble.;John R Davies.;Kare H Tang.;Robert Gerber.;Graham Cole.;Peter O'Kane.;Andrew S P Sharp.;Ramzi Khamis.;Gajen Kanaganayagam.;Ricardo Petraco.;Neil Ruparelia.;Iqbal S Malik.;Sukhjinder Nijjer.;Sayan Sen.;Darrel P Francis.;Rasha Al-Lamee.
来源: Circ Cardiovasc Interv. 2021年14卷8期e009891页
[Figure: see text].
483. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.
作者: Jonathan P Piccini.;Christopher Dufton.;Ian A Carroll.;Jeff S Healey.;William T Abraham.;Yaariv Khaykin.;Ryan Aleong.;Steven K Krueger.;William H Sauer.;Stephen B Wilton.;Michiel Rienstra.;Dirk J van Veldhuisen.;Inder S Anand.;Michel White.;A John Camm.;Paul D Ziegler.;Debra Marshall.;Michael R Bristow.;Stuart J Connolly.; .
来源: Circ Arrhythm Electrophysiol. 2021年14卷8期e009591页
[Figure: see text].
484. Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
作者: Rasmus S Ripa.;Emilie H Zobel.;Bernt J von Scholten.;Jacob K Jensen.;Tina Binderup.;Lars J Diaz.;Viktor R Curovic.;Tine W Hansen.;Peter Rossing.;Andreas Kjaer.
来源: Circ Cardiovasc Imaging. 2021年14卷7期e012174页
The mechanism behind the cardiovascular protection observed with human GLP-1 RA (glucagon-like peptide-1 receptor agonists) in type 2 diabetes is unknown. We hypothesized that treatment with the GLP-1 RA liraglutide had a positive effect on vascular inflammation.
485. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.
作者: Moritz Döbert.;Anna Nektaria Varouxaki.;An Chi Mu.;Argyro Syngelaki.;Anca Ciobanu.;Ranjit Akolekar.;Catalina De Paco Matallana.;Simona Cicero.;Elena Greco.;Mandeep Singh.;Deepa Janga.;Maria Del Mar Gil.;Jacques C Jani.;José Luis Bartha.;Kate Maclagan.;David Wright.;Kypros H Nicolaides.
来源: Circulation. 2021年144卷9期670-679页
Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ≈75% at a screen-positive rate of 10%. However, there is no known intervention to reduce the incidence of the disease.
486. Improving the Effectiveness of Psychological Interventions for Depression and Anxiety in Cardiac Rehabilitation: PATHWAY-A Single-Blind, Parallel, Randomized, Controlled Trial of Group Metacognitive Therapy.
作者: Adrian Wells.;David Reeves.;Lora Capobianco.;Calvin Heal.;Linda Davies.;Anthony Heagerty.;Patrick Doherty.;Peter Fisher.
来源: Circulation. 2021年144卷1期23-33页
Depression and anxiety in cardiovascular disease are significant, contributing to poor prognosis. Unfortunately, current psychological treatments offer mixed, usually small improvements in these symptoms. The present trial tested for the first time the effects of group metacognitive therapy (MCT; 6 sessions) on anxiety and depressive symptoms when delivered alongside cardiac rehabilitation (CR).
487. Personalized, Electronic Health Record-Integrated Decision Aid for Stroke Prevention in Atrial Fibrillation: A Small Cluster Randomized Trial and Qualitative Analysis of Efficacy and Acceptability.
作者: Stacey L Schott.;Julia Berkowitz.;Shayne E Dodge.;Curtis L Petersen.;Catherine H Saunders.;Navjot Kaur Sobti.;Keren Xu.;Megan Coylewright.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷6期e007329页
Shared decision-making in cardiology is increasingly recommended to improve patient-centeredness of care. Decision aids can improve patient knowledge and decisional quality but are infrequently used in real-world practice. This mixed-methods study tests the efficacy and acceptability of a decision aid integrated into the electronic health record (Integrated Decision Aid [IDeA]) and delivered by clinicians for patients with atrial fibrillation considering options to reduce stroke risk. We aimed to determine whether the IDeA improves patient knowledge, reduces decisional conflict, and is seen as acceptable by clinicians and patients.
488. Atherectomy and Drug-Coated Balloon Angioplasty for the Treatment of Long Infrapopliteal Lesions: A Randomized Controlled Trial.
作者: Aljoscha Rastan.;Marianne Brodmann.;Tanja Böhme.;Roland Macharzina.;Elias Noory.;Ulrich Beschorner.;Peter-Christian Flügel.;Karlheinz Bürgelin.;Franz-Josef Neumann.;Thomas Zeller.
来源: Circ Cardiovasc Interv. 2021年14卷6期e010280页
Prospective, randomized, multicenter trials show no beneficial impact of drug-coated balloon (DCB) therapy alone on the technical and clinical outcomes of infrapopliteal artery lesions in comparison to plain old balloon angioplasty. The aim of this study was to evaluate the performance of directional atherectomy (DA) plus DCB angioplasty versus DCB alone in treatment of long infrapopliteal artery lesions.
489. Health-Related Quality of Life and Angina in Fractional Flow Reserve- Versus Angiography-Guided Coronary Artery Bypass Grafting: FARGO Trial (Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization).
作者: Anne Langhoff Thuesen.;Lars Peter Riber.;Karsten Tange Veien.;Evald Høj Christiansen.;Svend Eggert Jensen.;Ivy Modrau.;Jan Jesper Andreasen.;Britt Borregaard.;Anders Junker.;Poul Erik Mortensen.;Lisette Okkels Jensen.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷6期e007302页
In coronary artery bypass grafting (CABG), the use of fractional flow reserve (FFR) is insufficiently investigated. Stenosis assessment usually relies on visual estimates of lesion severity. This study evaluated health-related quality of life (HRQoL) and angina after FFR- versus angiography-guided CABG.
490. Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
作者: Jesper Jensen.;Massar Omar.;Caroline Kistorp.;Christian Tuxen.;Ida Gustafsson.;Lars Køber.;Finn Gustafsson.;Jens Faber.;Julie L Forman.;Jacob E Møller.;Morten Schou.
来源: Circulation. 2021年143卷22期2208-2210页 491. Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study.
作者: Kuniaki Takahashi.;Patrick W Serruys.;Chao Gao.;Masafumi Ono.;Rutao Wang.;Daniel J F M Thuijs.;Michael J Mack.;Nick Curzen.;Friedrich-Wilhelm Mohr.;Piroze Davierwala.;Milan Milojevic.;Joanna J Wykrzykowska.;Robbert J de Winter.;Faisal Sharif.;Yoshinobu Onuma.;Stuart J Head.;Arie Pieter Kappetein.;Marie-Claude Morice.;David R Holmes.; .
来源: Circulation. 2021年144卷2期96-109页
Ten-year all-cause death according to incomplete (IR) versus complete revascularization (CR) has not been fully investigated in patients with 3-vessel disease and left main coronary artery disease undergoing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG).
492. Changes in Home Blood Pressure Monitored Among Elderly Patients With Hypertension During the COVID-19 Outbreak: A Longitudinal Study in China Leveraging a Smartphone-Based Application.
作者: Shuyuan Zhang.;Xiaoyang Zhou.;Youren Chen.;Lixin Wang.;Bingpo Zhu.;Yinong Jiang.;Peili Bu.;Wei Liu.;Dianfang Li.;Yuming Li.;Yanhua Tao.;Jie Ren.;Li Fu.;Yufeng Li.;Xiaomei Shen.;Hualing Liu.;Gang Sun.;Xinjuan Xu.;Jingjing Bai.;Weili Zhang.;Jun Cai.; .
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷5期e007098页
The coronavirus disease 2019 (COVID-19) pandemic has impacted clinical care worldwide. Evidence of how this health crisis affected common conditions like blood pressure (BP) control is uncertain.
493. Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI Pilot Trial.
作者: Justin Cole.;Nay Htun.;Robert Lew.;Mark Freilich.;Stephen Quinn.;Jamie Layland.
来源: Circ Cardiovasc Interv. 2021年14卷5期e009992页
Periprocedural myocardial infarction and injury (PM-injury) are the most common complications of percutaneous coronary intervention (PCI) and are associated with future adverse cardiac events. Inflammation plays a pivotal role in the development of PM-injury. In this randomized pilot trial, we assessed the effect of an anti-inflammatory medication colchicine on periprocedural myocardial injury.
494. Plasma Proteomic Profile Predicts Survival in Heart Failure With Reduced Ejection Fraction.
作者: Hongsheng Gui.;Ruicong She.;Jasmine Luzum.;Jia Li.;Timothy D Bryson.;Yigal Pinto.;Hani N Sabbah.;L Keoki Williams.;David E Lanfear.
来源: Circ Genom Precis Med. 2021年14卷3期e003140页
It remains unclear whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS).
495. Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS.
作者: Kristina Lambrakis.;Cynthia Papendick.;John K French.;Stephen Quinn.;Andrew Blyth.;Anil Seshadri.;Michael J R Edmonds.;Anthony Chuang.;Ehsan Khan.;Adam J Nelson.;Deborah Wright.;Matthew Horsfall.;Erin Morton.;Jonathan Karnon.;Tom Briffa.;Louise A Cullen.;Derek P Chew.
来源: Circulation. 2021年144卷2期113-125页
High-sensitivity troponin assays are increasingly being adopted to expedite evaluation of patients with suspected acute coronary syndromes. Few direct comparisons have examined whether the enhanced performance of these assays at low concentrations leads to changes in care that improves longer-term outcomes. This study evaluated late outcomes of participants managed under an unmasked 0/1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol compared with a 0/3-hour masked hs-cTnT protocol.
496. Text Message Medication Adherence Reminders Automated and Delivered at Scale Across Two Institutions: Testing the Nudge System: Pilot Study.
作者: Phat Luong.;Thomas J Glorioso.;Gary K Grunwald.;Pamela Peterson.;Larry A Allen.;Amber Khanna.;Joy Waughtal.;Lisa Sandy.;P Michael Ho.;Sheana Bull.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷5期e007015页
Medication refill behavior in patients with cardiovascular diseases is suboptimal. Brief behavioral interventions called Nudges may impact medication refill behavior and can be delivered at scale to patients using text messaging.
497. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
作者: Siri Lagethon Heck.;Albulena Mecinaj.;Anne Hansen Ree.;Pavel Hoffmann.;Jeanette Schulz-Menger.;Morten Wang Fagerland.;Berit Gravdehaug.;Helge Røsjø.;Kjetil Steine.;Jürgen Geisler.;Geeta Gulati.;Torbjørn Omland.
来源: Circulation. 2021年143卷25期2431-2440页
Adjuvant breast cancer therapy containing anthracyclines with or without anti-human epidermal growth factor receptor-2 antibodies and radiotherapy is associated with cancer treatment-related cardiac dysfunction. In the PRADA trial (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy), concomitant treatment with the angiotensin receptor blocker candesartan attenuated the reduction in left ventricular ejection fraction (LVEF) in women receiving treatment for breast cancer, whereas the β-blocker metoprolol attenuated the increase in cardiac troponins. This study aimed to assess the long-term effects of candesartan and metoprolol or their combination to prevent a reduction in cardiac function and myocardial injury.
498. Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.
作者: Tania A Pawade.;Mhairi K Doris.;Rong Bing.;Audrey C White.;Laura Forsyth.;Emily Evans.;Catriona Graham.;Michelle C Williams.;Edwin J R van Beek.;Alison Fletcher.;Philip D Adamson.;Jack P M Andrews.;Timothy R G Cartlidge.;William S A Jenkins.;Maaz Syed.;Takeshi Fujisawa.;Christophe Lucatelli.;William Fraser.;Stuart H Ralston.;Nicholas Boon.;Bernard Prendergast.;David E Newby.;Marc R Dweck.
来源: Circulation. 2021年143卷25期2418-2427页
Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis.
499. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
作者: Jasper Tromp.;Brian L Claggett.;Jiankang Liu.;Alice M Jackson.;Pardeep S Jhund.;Lars Køber.;Jiří Widimský.;Sergey A Boytsov.;Vijay K Chopra.;Inder S Anand.;Junbo Ge.;Chen-Huan Chen.;Aldo P Maggioni.;Felipe Martinez.;Milton Packer.;Marc A Pfeffer.;Burkert Pieske.;Margaret M Redfield.;Jean L Rouleau.;Dirk J Van Veldhuisen.;Faiez Zannad.;Michael R Zile.;Adel R Rizkala.;Akiko Inubushi-Molessa.;Martin P Lefkowitz.;Victor C Shi.;John J V McMurray.;Scott D Solomon.;Carolyn S P Lam.; .
来源: Circ Heart Fail. 2021年14卷4期e007901页
Heart failure with preserved ejection fraction (HFpEF) is a global public health problem with important regional differences. We investigated these differences in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF), the largest and most inclusive global HFpEF trial.
500. Treatment-Related Changes in Left Atrial Structure in Atrial Fibrillation: Findings From the CABANA Imaging Substudy.
作者: Maryam E Rettmann.;David R Holmes.;Kristi H Monahan.;Jerome F Breen.;Tristram D Bahnson.;Daniel B Mark.;Jeanne E Poole.;Alicia M Ellis.;Adam P Silverstein.;Hussein R Al-Khalidi.;Kerry L Lee.;Richard A Robb.;Douglas L Packer.; .
来源: Circ Arrhythm Electrophysiol. 2021年14卷5期e008540页
[Figure: see text].
|